AL amyloidosis requires aggressive therapy targeting the underlying plasma cell disorder, such as chemotherapy or stem cell transplantation, as untreated AL amyloidosis progresses rapidly and has poor prognosis.18 On the other hand, ATTR is managed with Tafamidis, a transthyretin tetramer stabilizer. This evidence concerns the gene TTR and AL amyloidosis.